secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066947
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology completes enrollment in Phase 2 onvansertib trial for RAS-mutated mCRC; Q1 cash $79.9M
--------------------------------------------------------------------------------

- Completed enrollment in Phase 2 CRDF-004 trial of onvansertib + SoC for first-line RAS-mutated mCRC across 41 U.S. sites.
- Received second USPTO patent (No. 12,263,173) for onvansertib + bev in all bev-naïve mCRC patients, expiring no earlier than 2043.
- Cash and investments $79.9M as of March 31, 2025; projected runway into Q1 2027.
- Q1 2025 operating expenses $14.5M (up from $11.1M YoY); net cash used in ops $12.8M (up from $7.7M YoY).
- Additional CRDF-004 clinical data expected in first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000095017025066947/0000950170-25-066947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000095017025066947/crdf-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer